172 countries join COVAX to ensure equitable COVID-19 vaccine access

A total of 172 economies are currently engaged in discussions to join COVAX, a global initiative focused on ensuring equitable access to COVID-19 vaccines. This effort aims to collaborate with vaccine manufacturers to provide safe and effective vaccines to countries worldwide once they receive licensing and approval. COVAX boasts the largest and most diverse portfolio of COVID-19 vaccines, with nine candidates already in play and another nine under evaluation, while talks are ongoing with major producers.

The urgency of this initiative arises from the need to protect vulnerable populations, such as healthcare workers and the elderly, from the COVID-19 virus. In order to secure sufficient vaccine doses, COVAX is asking potential self-financing participants to confirm their intent to join the COVID-19 Vaccine Global Access Facility (COVAX Facility) by August 31. These expressions of interest must then be converted into binding commitments by September 18, with initial payments required by October 9. This timeline underscores the critical need for swift action to ensure that vaccines are available as soon as possible.

Stefan Löfven, the Prime Minister of Sweden, emphasized the importance of equal access to vaccines, stating, “This cannot be a race with a few winners.” He highlighted that the COVAX Facility is essential for ensuring that all countries have access to the largest portfolio of vaccine candidates and that distribution is fair and equitable. The COVAX Facility operates as a pooled procurement mechanism, leveraging the collective buying power of participating economies to secure volume guarantees from vaccine manufacturers, which aids in the rapid production of vaccines.

The success of the COVAX initiative depends not only on the commitment of countries to join but also on addressing significant funding gaps for research and development and supporting the participation of lower-income economies. The collaboration between governments, researchers, and manufacturers is vital for overcoming the unprecedented global health challenge posed by COVID-19 and ensuring that vaccines are distributed fairly around the world.